5 results on '"Rascon, Javier"'
Number of results to display per page
Search Results
2. Off-label use of rituximab for systemic lupus erythematosus in Europe
- Author
-
Ryden-Aulin, Monica, Boumpas, Dimitrios, Bultink, Irene, Rubio, Jose Luis Callejas, Caminal-Montero, Luis, Castro, Antoni, Colodro Ruiz, Agustin, Doria, Andrea, Domer, Thomas, Gonzalez-Echavarri, Cristina, Gremese, Elisa, Houssiau, Frederic A., Huizinga, Tom, Inana, Murat, Isenberg, David, Luliano, Annamaria, Jacobsen, Soren, Jimenez-Alonso, Juan, Kovacs, Laszlo, Mariette, Xavier, Mosca, Marta, Nived, Ola, Oristrell, Joaquim, Ramos-Casals, Manuel, Rascon, Javier, Ruiz-Irastorza, Guillermo, Saez-Comet, Luis, Salvador Cervello, Gonzalo, Cervello, Gonzalo Salvador, Sebastiani, Gian Domenico, Squatrito, Danilo, Szucs, Gabriella, Voskuyl, Alexandre, van Vollenhoven, Ronald, Rheumatology, AII - Inflammatory diseases, [Ryden-Aulin, Monica] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Unit Clin Therapy Res, Stockholm, Sweden, [van Vollenhoven, Ronald] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Unit Clin Therapy Res, Stockholm, Sweden, [Boumpas, Dimitrios] Natl & Kapodestrian Univ Athens, Attikon Univ Hosp, Joint Acad Rheumatol Program, Med Sch, Athens, Greece, [Boumpas, Dimitrios] Natl & Kapodestrian Univ Athens, Attikon Univ Hosp, Dept Med 4, Med Sch, Athens, Greece, [Bultink, Irene] Amsterdam Rheumatol & Immunol Ctr, Tepartment Rheumatol, Amsterdam, Netherlands, [Rubio, Jose Luis Callejas] Hosp San Cecilio, Unit Autoimmune Dis, Granada, Spain, [Caminal-Montero, Luis] Hosp Univ Cent Asturias, Internal Med Dept, Autoimmune System Dis Unit, Oviedo, Spain, [Castro, Antoni] Rovira & Virgili Univ URV, Univ Hosp Sant Joan Reus, lnternal Med Dept Univ, IISPV, Reus, Spain, [Colodro Ruiz, Agustin] Pasaje Nueva Victoria,2,2do C, Jaen, Spain, [Doria, Andrea] Univ Padua, Dept Med, Rheumatol Unit, Padua, Italy, [Domer, Thomas] Charite Univ Med Berlin, Dept Med Rheumatol & Clin Immunol, Berlin, Germany, [Gonzalez-Echavarri, Cristina] Univ Basque Country, Cruces Univ Hosp, BioCruces Hlth Res Inst, Autoimmune Dis Res Unit,Dept Internal Med, Baracaldo, Spain, [Ruiz-Irastorza, Guillermo] Univ Basque Country, Cruces Univ Hosp, BioCruces Hlth Res Inst, Autoimmune Dis Res Unit,Dept Internal Med, Baracaldo, Spain, [Gremese, Elisa] Univ Cattolica Sacro Cuore, Inst Rheumatol & Affine Sci IRSA, Rome, Italy, [Houssiau, Frederic A.] Catholic Univ Louvain, Pole Pathol Rhumatismales Inflammatoires & Syst, Clin Univ St Luc, Serv Rhumatol, Brussels, Belgium, [Huizinga, Tom] Leiden Univ, Med Ctr, Dept Rheumatol, C1-41, Leiden, Netherlands, [Inana, Murat] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Rheumatol, Istanbul, Turkey, [Isenberg, David] UCL, Rayne Bldg, London, England, [Luliano, Annamaria] San Camillo Hosp, Rheumatol Unit, Rome, Italy, [Jacobsen, Soren] Univ Copenhagen, Rigshosp, Ctr Rheumatol & Spine Dis, Copenhagen Lupus & Vasculitis Clin, Copenhagen, Denmark, [Jimenez-Alonso, Juan] Univ Virgen Nieves Hosp, lnternal Dept, Granada, Spain, [Kovacs, Laszlo] Univ Szeged, Albert Szent Gyorgyi Hlth Ctr, Fac Med, Dept Rheumatol, Szeged, Hungary, [Mariette, Xavier] Univ Paris Sud, Hopitaux Univ Paris Sud, Rhumatol Responsable Unite Rech Clin, INSERM U1184, Paris, France, [Mosca, Marta] Rheumatol Unit, Pisa, Italy, [Nived, Ola] Skane Univ Hosp, Rheumatol Clin, Lund, Sweden, [Oristrell, Joaquim] Univ Autonoma Barcelona, Hosp Sabadell, Internal Med Dept, Catalunya, Spain, [Ramos-Casals, Manuel] CELLEX IDIBAPS, Josep Font Autoimmune Lab, ICMiD, Dept Autoimmune Dis, Barcelona, Spain, [Rascon, Javier] Carrer Sabateres, 9-1,Alare, Islas Baleares, Spain, [Saez-Comet, Luis] Hosp Univ Miguel Servet Zaragoza, Unidad Enfermedades Autoinmunes Sistem, Paseo Isabel Catolica, Zaragoza, Spain, [Salvador Cervello, Gonzalo] Hosp Univ & Politecn La Fe, Inmunopathol & Autoimmune Area, Dept Internal Med, Valencia, Spain, [Sebastiani, Gian Domenico] Osped San Camillo, UOC Reumatol, Circonvallaz Gianicolense 87, Rome, Italy, [Squatrito, Danilo] Univ Florence, Dept Sperimental & Clin Med, Florence, Italy, [Szucs, Gabriella] Univ Debrecen, Inst Med, Dept Rheumatol, Debrecen, Hungary, [Voskuyl, Alexandre] Vrije Univ Amsterdam, Med Ctr, Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam, Netherlands, [van Vollenhoven, Ronald] Karolinska Univ Hosp Stockholm, Rheumatol Clin, Stockholm, Sweden, [van Vollenhoven, Ronald] Amsterdam Rheumatol & Immunol Ctr ARC, AMC Mail F4-105, Amsterdam, Netherlands, MSD, Lilly Netherlands, Roche, UCB, Sanofi, and RvV
- Subjects
medicine.medical_specialty ,Disease duration ,Immunology ,Lupus nephritis ,DMARDs (biologic) ,Klinikai orvostudományok ,Off-label use ,Systemic Lupus Erythematosus ,Article ,Disease activity ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Internal medicine ,medicine ,Lupus Nephritis ,Medicine (all) ,In patient ,030212 general & internal medicine ,skin and connective tissue diseases ,030203 arthritis & rheumatology ,business.industry ,Orvostudományok ,General Medicine ,medicine.disease ,Disease control ,3. Good health ,Rituximab ,business ,medicine.drug - Abstract
OBJECTIVES: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy.METHODS: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries.RESULTS: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy.CONCLUSIONS: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.
- Published
- 2016
- Full Text
- View/download PDF
3. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label
- Author
-
Diaz-Lagares, Candido, Perez-Alvarez, Roberto, Garcia-Hernandez, Francisco J., Ayala-Gutierrez, Maria M., Luis Callejas, Jose, Martinez-Berriotxoa, Agustin, Rascon, Javier, Caminal-Montero, Luis, Selva-O'Callaghan, Albert, Oristrell, Joaquim, Hidalgo, Carmen, Gomez-de-la-Torre, Ricardo, Saez, Luis, Canora-Lebrato, Jesus, Camps, Maria-Teresa, Ortego-Centeno, Norberto, Castillo-Palma, Maria-Jesus, Ramos-Casals, Manuel, and BIOGEAS Study Grp
- Subjects
Male ,modelos de riesgos proporcionales ,humanos ,enfermedades autoinmunes ,adolescente ,Kaplan-Meier Estimate ,vasculitis ,Etanercept ,rituximab ,Infection rate ,systemic lupus erythematosus ,Risk Factors ,adalimumab ,Immunology and Allergy ,Sjogren syndrome ,Young adult ,mediana edad ,Aged, 80 and over ,anciano ,Middle Aged ,adulto ,adulto joven ,Female ,productos biológicos ,Rituximab ,prescripción en indicaciones no aprobadas ,Infection ,Vasculitis ,Research Article ,medicine.drug ,Adult ,estimación de Kaplan-Meier ,medicine.medical_specialty ,Adolescent ,Immunology ,macromolecular substances ,Infections ,Autoimmune Diseases ,Young Adult ,Rheumatology ,Internal medicine ,Adalimumab ,medicine ,Humans ,factores de riesgo ,Aged ,Proportional Hazards Models ,Biological Products ,business.industry ,Off-Label Use ,infección ,medicine.disease ,Sjögren syndrome ,Infliximab ,Observational study ,infliximab ,business ,etanercept - Abstract
Introduction: The purpose of this observational study was to analyze the rates, characteristics and associated risk factors of severe infections in patients with systemic autoimmune diseases (SAD) who were treated off-label with biological agents in daily practice. Methods: The BIOGEAS registry is an ongoing Spanish prospective cohort study investigating the long-term safety and efficacy of the off-label use of biological agents in adult patients with severe, refractory SAD. Severe infections were defined according to previous studies as those that required intravenous treatment or that led to hospitalization or death. Patients contributed person-years of follow-up for the period in which they were treated with biological agents. Results: A total of 344 patients with SAD treated with biological agents off-label were included in the Registry until July 2010. The first biological therapies included rituximab in 264 (77%) patients, infliximab in 37 (11%), etanercept in 21 (6%), adalimumab in 19 (5%), and 'other' agents in 3 (1%). Forty-five severe infections occurred in 37 patients after a mean follow-up of 26.76 months. These infections resulted in four deaths. The crude rate of severe infections was 90.9 events/1000 person-years (112.5 for rituximab, 76.9 for infliximab, 66.9 for adalimumab and 30.5 for etanercept respectively). In patients treated with more than two courses of rituximab, the crude rate of severe infection was 226.4 events/1000 person-years. A pathogen was identified in 24 (53%) severe infections. The most common sites of severe infection were the lower respiratory tract (39%), bacteremia/sepsis (20%) and the urinary tract (16%). There were no significant differences relating to gender, SAD, agent, other previous therapies, number of previous immunosuppressive agents received or other therapies administered concomitantly. Cox regression analysis showed that age (P = 0.015) was independently associated with an increased risk of severe infection. Survival curves showed a lower survival rate in patients with severe infections (log-rank and Breslow tests < 0.001). Conclusions: The rates of severe infections in SAD patients with severe, refractory disease treated depended on the biological agent used, with the highest rates being observed for rituximab and the lowest for etanercept. The rate of infection was especially high in patients receiving three or more courses of rituximab. In patients with severe infections, survival was significantly reduced. Older age was the only significant predictive factor of severe infection., The BIOGEAS Study group has received educational grants from Roche and Abbott supporting the design and maintenance of the webpage [35]. All authors have declared no conflicts of interest. None has received grants from these laboratories or conducted clinical trials with rituximab or etanercept as principal investigators or received honoraria as an Advisory Board member for Roche and Abbott. The financial support of Roche and Abbott is exclusively limited to maintaining the BIOGEAS webpage.
- Published
- 2011
- Full Text
- View/download PDF
4. Sarcoidosis as a Systemic Disease. Clinical and Epidemiological Characterization of Systemic Phenotype in 1521 Patients
- Author
-
Retamozo, Soledad, Perez-Alvarez, Roberto, Feijoo-Masso, Carlos, Escalante, Begona, Gonzalez-Garcia, Andres, Chara-Cervantes, Joel, Gomez La Torre, Ricardo, Lopez Dupla, Miguel, Alguacil, Ana, Rascon, Javier, Perez-Conesa, Mercedes, Bonet, Mariona, Robles, Angel, Luis Callejas, Jose, Pinilla, Blanca, Fonseca Aizpuru, Eva, Perez Guerrero, Patricia, José-Salvador García-Morillo, Miguel, Borja, Akasbi, Miriam, Ojea Varona, Silvia, La Red Bellvis, Gloria, Calvo Begueria, Eva, Gomez Cerezo, Jorge Francisco, Soler I Ferrer, Cristina, Peral Gutierrez Ceballos, Enrique, Cruz-Caparros, Gracia, Rodriguez Fernandez, Sergio, Gato Diez, Alberto, Morcillo, Cesar, Ojeda, Inmaculada, Jose Vives, M., Penades Vidal, Maria, Vicente, Moises, Kostov, Belchin, Pallares, Lucio, Brito-Zeron, Pilar, and Ramos-Casals, Manuel
5. Musculoskeletal Sarcoidosis: Characterization and Clinical Expression of 129 Patients with Granulomatous Infiltration of Bones And/or Muscles
- Author
-
Retamozo, Soledad, Perez-Alvarez, Roberto, Bueno Juana, Esperanza, Feijoo-Masso, Carlos, Gonzalez-Garcia, Andres, Chara-Cervantes, Joel, Yllera Gutierrez, Carmen, Lopez Dupla, Miguel, Alguacil, Ana, Rascon, Javier, Perez-Conesa, Mercedes, Bonet, Mariona, Robles, Angel, Luis Callejas, Jose, Toledo Samaniego, Neera, Fonseca Aizpuru, Eva, Perez Guerrero, Patricia, Garcia Morillo, Jose Salvador, Miguel, Borja, Akasbi, Miriam, Tejera Perez, Rosa, La Red Bellvis, Gloria, Calvo Begueria, Eva, Gomez Cerezo, Jorge Francisco, Gomez Lozano, Albert, Gutierrez Ceballos, Enrique Peral, Cruz-Caparros, Gracia, Rodriguez Fernandez, Sergio, Gato Diez, Alberto, Morcillo, Cesar, Ojeda, Inmaculada, Jose Vives, M., Penades Vidal, Maria, Vicente, Moises, Kostov, Belchin, Pallares, Lucio, Brito-Zeron, Pilar, and Manuel Ramos-Casals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.